THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed ...

Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of ...

My colon cancer journey showed me how compassionate doctors can change lives, as their kindness and care gave me strength and ...

From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is ...

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among ...

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

When deciding if reoperation is an option in recurrent glioblastoma, factors like tumor location, therapy history and patient health should be considered.